Scientific research has confirmed that treatment with the popular probiotic supplement Prescript-Assist is associated with significant reductions in symptoms in people with Irritable Bowel Syndrome.
Prescript-Assist™ is a soil-based probiotic containing 29 highly resilient strains of beneficial bacteria, combined with a humic/fulvic acid prebiotic that enhances SBO (soil based organism) proliferation.
Prescript-Assist also contains Bacillus subtilis, which is a proven probiotic species found in traditional foods.
One of the most significant benefits of Prescript-Assist over many other traditional lactic-acid based probiotic supplements is that it doesn’t require refrigeration and is shelf stable, with 95% viability two years after the date of manufacture (without refrigeration).
Many probiotic supplements can be largely worthless by the time they have sat on the warm shelves of health food stores for months with no refrigeration, causing huge losses to the bacterial count.
Prescript-Assist is one of the few probiotic supplements on the market, which is also backed by peer-reviewed, double-blind, placebo-controlled clinical research Pliris Soft, including a one-year follow-up study as a treatment for irritable bowel syndrome.
Irritable Bowel Syndrome (IBS) is a very common, chronic digestive condition that can cause symptoms such as constipation, diarrhea, bloating, flatulence and stomach cramps.
A number of scientific studies have now indicated that alterations in the intestinal gut microflora such as dysbiosis to play a role in the pathophysiology of IBS(irritable bowel syndrome).
Prescript-Assist Probiotic Scientific Research
The double-blind study from 2005 was conducted primarily to compare the effects of Prescript-Assist with placebo in patients with a diagnosis of Irritable Bowel Syndrome(IBS).
Toward this objective, a secondary methodologic goal was to determine the number and nature of symptom clusters( “subsyndromic factors”) that characterize IBS.
The study identified 3 subsyndromic factors of IBS: general ill feelings/nausea, indigestion/flatulence, and colitis.
In this, methodologically oriented double-blind study in patients with IBS, combined probiotic-prebiotic treatment with Prescript-Assist was associated with significant reductions in these factors.
In the 2007 open-label, partially controlled, 1-year( 14 [2] months) extension study, treatment with Prescript-Assist probiotic was associated with a continued reduction in IBS symptoms such as general ill feelings/nausea, indigestion/flatulence and colitis.
At the 52-week follow-up, the rate of remissions was 81.5% to 100%.
The year extension study concluded:
Based on the results from the present 1-year extension study, treatment with this probiotic-prebiotic complex may be an option for short-term( 2-4 weeks) and long-term( approximately 60-week) reductions in IBS symptoms.
